Notably, metreleptin (a leptin analogue), setmelanotide (a melanocortin‐4 (MC4) receptor agonist), phentermine/topiramate (a norepinephrine agonist/g This figure was created using BioRender (https://biorender.com/) amma‐aminobutyric acid agonist and glutamate antagonist) and naltrexone/bupropion (an opioid receptor antagonist and dopamine/norepinephrine reuptake inhibitor), as well as the (glucagon‐like peptide 1) GLP1 agonists liraglutide and semaglutide, have been approved for the treatment of obesity [13]. This evidence concerns the gene GCG and obesity disorder.